Washington, D.C. (January 29, 2021) — Brett McReynolds, Vice President of Programs and Public Policy at the American Autoimmune Related Diseases Association, released the following statement in response HHS’ decision to delay implementation of the final rebate rule that would help direct PBM savings to patients:
“We recognize the importance of reviewing pending rulings from previous administrations, but we strongly encourage the Biden Administration to act promptly and without further delay to implement this rule that will directly benefit the tens of millions of Americans with one or more autoimmune diseases. Stated simply, many don’t have the luxury of waiting to get access to the treatments that they rely upon. Delaying implementation would have significant negative implications on patients, particularly seniors who have been disproportionally impacted by the COVID-19 pandemic.
“We stand ready to work with the administration to ensure that the voice of patients remains front and center in any future decisions. Given that millions of families struggling with high out of pocket costs and facing long-term uncertainty, we think this is a straightforward one.”
For more information about AARDA and its programs, visit www.aarda.org.
American Autoimmune Related Diseases Association (AARDA) is the nation’s only nonprofit organization dedicated to bringing a national focus to autoimmunity as a category of disease and a major women’s health issue and promoting a collaborative research effort in order to find better treatments and a cure for all autoimmune diseases. For more information, visit www.aarda.org. Follow us on social media: Facebook (www.facebook.com/Autoimmunity), Twitter (@AARDATweets), Instagram (@autoimmune_diseases), and YouTube (www.youtube.com/AARDATube)